A luciferin analogue generating near-infrared bioluminescence achieves highly sensitive deep-tissue imaging.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 27297211.
- Also identified by DOI 10.1038/ncomms11856 and PMC identifier 4911627.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
In preclinical cancer research, bioluminescence imaging with firefly luciferase and D-luciferin has become a standard to monitor biological processes both in vitro and in vivo. However, the emission maximum (λmax) of bioluminescence produced by D-luciferin is 562 nm where light is not highly penetrable in biological tissues. This emphasizes a need for developing a red-shifted bioluminescence imaging system to improve detection sensitivity of targets in deep tissue. Here we characterize the bioluminescent properties of the newly synthesized luciferin analogue, AkaLumine-HCl. The bioluminescence produced by AkaLumine-HCl in reactions with native firefly luciferase is in the near-infrared wavelength ranges (λmax=677 nm), and yields significantly increased target-detection sensitivity from deep tissues with maximal signals attained at very low concentrations, as compared with D-luciferin and emerging synthetic luciferin CycLuc1. These characteristics offer a more sensitive and accurate method for non-invasive bioluminescence imaging with native firefly luciferase in various animal models.
Medical subject headings
- Diagnostic Imaging
- Firefly Luciferin
- Luciferases, Firefly
- Luminescent Measurements
- Lung Neoplasms
- Spectroscopy, Near-Infrared